Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565762 | 0.94 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAADRB2HTR1B | |
| SCHEMBL24477365 | 0.92 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4ELMNAADRB2 | |
| SCHEMBL16692608 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4ELMNAADRB2 | |
| SCHEMBL17806160 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4ELMNAADRB2 | |
| SCHEMBL26172913 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4ELMNAADRB2 | |
| SCHEMBL21401391 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4ELMNAADRB2 | |
| SCHEMBL6552923 | 0.87 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19LMNA | |
| SCHEMBL25565755 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19LMNA | |
| SCHEMBL12703408 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAADRB2HTR1B | |
| SCHEMBL11044686 | 0.82 | CYP2C19 (0.48) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | ALDH1A1 3979/4885SMN1; SMN2 122/4885CYP1A2 4870/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | ALDH1A1 3422/4885SMN1; SMN2 99/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.